Teva, Sanofi’s Duvakitug maintains efficacy through 44 weeks in Phase 2b study
SNY•Teva and Sanofi reported sustained symptom relief and reduced intestinal inflammation through 44 weeks in a Phase 2b extension study of duvakitug for ulcerative colitis and Crohn’s disease.
1. Extension study results
Results presented at UEG Week 2026 showed that higher-dose treatment produced numerically better outcomes in both diseases. Duvakitug was generally well tolerated, with no new safety concerns and few treatment discontinuations due to adverse events; the investigational drug is undergoing Phase 3 trials in both diseases.
